Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: A randomised, crossover, placebo-controlled study

Drugs in R and D

Volumn 8, Issue 6, 2007, Pages 383-391

  Kasibhatta, Ravisekhar ^a   Naidu, M U R ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Drug interactions; Nevirapine, pharmacokinetics; Piperine, pharmacokinetics

Indexed keywords

NEVIMUNE; NEVIRAPINE; PIPERINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 35548948992     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708060-00006     Document Type: Article

References (28)

1. UNAIDS: the Joint United Nations Programme on HIV/AIDS Web site [online]. Available at URL: http://www.unaids.org/Unaids/EN/Resources/Epidemiology/ epidemicupdates-lides.asp [Accessed 2004 Aug 17]
2. US Department of Health and Human Services (DHHS). HIV/AIDS medical practice guidelines [online]. Available at URL: http://www.aidsinfo.nih.gov/ guidelines/ [Accessed 2004 Aug 17]
3. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555-74
4. Van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987-99
5. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-73
6. Yozviak JL, Doerfler RE, Woodward WC. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice. HIV Clin Trials 2001; 2: 474-6
7. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364: 29-34
8. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial. The 2NN Study. Lancet 2004; 363: 1253-63
9. Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 11-9
10. Lamson MJ, Cort S, Sabo JP, et al. Assessment of nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharm Res 1995; 12: S-415
11. Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1999 Sep; 20 (6): 285-91
12. Viramune (nevirapine) [online]. Available from URL: http://www.rxlist. com/cgi/generic/nevira_cp.htm [Accessed 2007 Oct 19]
13. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999 Aug; 27 (8): 895-901
14. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65 (9): 1239-82
15. Baily DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10
16. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933-42
17. Atal CK, Zutshi U, Rao PG Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 1981; 4: 229-32
18. Zutshi RK, Singh R, Zutshi U, et al. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India 1985; 33: 223-4
19. Bano G, Raina RK, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41 (6): 615-7
20. Velpandian T, Jasuja R, Bhardwaj RK, et al. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001 Oct-Dec; 26 (4): 241-7
21. Koul IB, Kapil A. Evaluation of the liver protective potential of piperine, an active principle of black and long peppers. Planta Med 1993 Oct; 59 (5): 413-7
22. Singh J, Dubey RK, Atal CK. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986; 236: 488-93
23. Narang VS, Lulla A, Malhotra G, et al. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol 2005; 45: 265-74
24. Viramune (nevirapine) [product information]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, 1999
25. Pattanaik S, Hota D, Prabhakar S, et al. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006 Aug; 20 (8): 683-6
26. King JR, Yogev R, Aldrovandi G, et al. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. HIV Clin Trials 2004 Sep-Oct; 5 (5): 288-93
27. Bhardwaj RK, Glaeser H, Becquemont L, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Experiment Therapeut 2002; 302: 645-50
28. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl. 1: S21-33